Considerations for Pharmacoepidemiological Studies of Drug-Cancer Associations.

In this MiniReview, we provide general considerations for the planning and conduct of pharmacoepidemiological studies of associations between drug use and cancer development. We address data sources, study design, assessment of drug exposure, ascertainment of cancer outcomes, confounder adjustment and future perspectives. Aspects of data sources include assessment of complete history of drug use and data on dose and duration of drug use, allowing estimates of cumulative exposure. Outcome data from formal cancer registries are preferable, but cancer data from other sources, for example, patient or pathology registries, medical records or claims are also suitable. The two principal designs for observational studies evaluating drug-cancer associations are the cohort and case-control designs. A key challenge in studies of drug-cancer associations is the exposure assessment due to the typically long period of cancer development. We present methods to examine early and late effects of drug use on cancer development and discuss the need for employing 'lag-time' in order to avoid reverse causation. We emphasize that a new-user study design should always be considered. We also underline the need for 'dose-response' analyses, as drug-cancer associations are likely to be dose-dependent. Generally, studies of drug-cancer associations should explore risk of site-specific cancer, rather than cancer overall. Additional differentiation may also be crucial for organ-specific cancer with various distinct histological subtypes (e.g., lung or ovary cancer). We also highlight the influence of confounding factors and discuss various methods to address confounding, while emphasizing that the choices of methods depend on the design and specific objectives of the individual study. In some studies, use of active comparator(s) may be preferable. Pharmacoepidemiological studies of drug-cancer associations are expected to evolve considerably in the coming years, due to the increasing availability of long-term data on drug exposures and cancer outcomes, the increasing conduct of multinational studies, allowing studies of rare cancers and subtypes of cancer, and methodological improvements specifically addressing cancer and other long-term outcomes.

[1]  T. Stürmer,et al.  Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes , 2018, Diabetes, obesity & metabolism.

[2]  James M Robins,et al.  Per-Protocol Analyses of Pragmatic Trials. , 2017, The New England journal of medicine.

[3]  T. Stürmer,et al.  Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women , 2017, Epidemiology.

[4]  M. Pabon,et al.  Basic aspects of the pathogenesis and prevention of non‐melanoma skin cancer in solid organ transplant recipients: a review , 2017, International journal of dermatology.

[5]  Jesper Hallas,et al.  New use of prescription drugs prior to a cancer diagnosis , 2016, Pharmacoepidemiology and drug safety.

[6]  B. Wettermark,et al.  The First Decade with the Swedish Prescribed Drug Register – A Systematic Review of the Output in the Scientific Literature , 2016, Basic & clinical pharmacology & toxicology.

[7]  H. Sørensen,et al.  Data Resource Profile: The Danish National Prescription Registry , 2016, International journal of epidemiology.

[8]  A. Walker For drug-induced carcinogenesis, the observations are the hypothesis: Invited editorial for the Mini-Symposium on Cancer Pharmacoepidemiology. , 2016, Annals of epidemiology.

[9]  H. Sørensen,et al.  Use of sildenafil or other phosphodiesterase inhibitors and risk of melanoma , 2016, British Journal of Cancer.

[10]  Rachael Williams,et al.  Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries , 2016, British Medical Journal.

[11]  D. Buist,et al.  Aspirin for the Prevention of Cancer Incidence and Mortality: Systematic Evidence Reviews for the U.S. Preventive Services Task Force , 2016, Annals of Internal Medicine.

[12]  M. Hernán,et al.  Adherence adjustment in the Coronary Drug Project: A call for better per-protocol effect estimates in randomized trials , 2016, Clinical trials.

[13]  Yin Cao,et al.  Aspirin and colorectal cancer: the promise of precision chemoprevention , 2016, Nature Reviews Cancer.

[14]  K. Straif,et al.  European Code against Cancer 4th Edition: Medical exposures, including hormone therapy, and cancer. , 2015, Cancer epidemiology.

[15]  David B Richardson,et al.  The Active Comparator, New User Study Design in Pharmacoepidemiology: Historical Foundations and Contemporary Application , 2015, Current Epidemiology Reports.

[16]  A. Kesselheim,et al.  The Safety of Prescription Drugs. , 2015, JAMA.

[17]  Ronac Mamtani,et al.  Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. , 2015, JAMA.

[18]  P. Stattin,et al.  Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma. , 2015, JAMA.

[19]  S. Suissa The Quasi-cohort approach in pharmacoepidemiology: upgrading the nested case-control. , 2015, Epidemiology.

[20]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[21]  V. Pate,et al.  Dipeptidyl‐peptidase‐4 inhibitors and pancreatic cancer: a cohort study , 2014, Diabetes, obesity & metabolism.

[22]  A. Berghöfer,et al.  Lithium and renal tumors: a critical comment to the report by Zaidan et al. , 2014, Kidney international.

[23]  B. Stengel,et al.  Increased risk of solid renal tumors in lithium-treated patients. , 2014, Kidney international.

[24]  M. J. van der Laan,et al.  Targeted Maximum Likelihood Estimation for Dynamic and Static Longitudinal Marginal Structural Working Models , 2014, Journal of causal inference.

[25]  R J Glynn,et al.  Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs , 2014, Journal of internal medicine.

[26]  J. Hallas,et al.  Use of self‐controlled designs in pharmacoepidemiology , 2014, Journal of internal medicine.

[27]  James M Robins,et al.  Randomized Trials Analyzed as Observational Studies , 2013, Annals of Internal Medicine.

[28]  N. McGranahan,et al.  The causes and consequences of genetic heterogeneity in cancer evolution , 2013, Nature.

[29]  Haibo Zhou,et al.  Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin , 2013, Diabetes Care.

[30]  K Furu,et al.  The Nordic prescription databases as a resource for pharmacoepidemiological research—a literature review , 2013, Pharmacoepidemiology and drug safety.

[31]  Jesper Hallas,et al.  Use of benzodiazepines or benzodiazepine related drugs and the risk of cancer: a population-based case-control study. , 2013, British journal of clinical pharmacology.

[32]  Brian Sauer,et al.  The incident user design in comparative effectiveness research , 2013, Pharmacoepidemiology and drug safety.

[33]  James M Robins,et al.  Structural Nested Cumulative Failure Time Models to Estimate the Effects of Interventions , 2012, Journal of the American Statistical Association.

[34]  Gianni Tognoni,et al.  Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials , 2012, The Lancet.

[35]  A. Israni,et al.  Spectrum of cancer risk among US solid organ transplant recipients. , 2011, JAMA.

[36]  W. Bilker,et al.  Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone , 2011, Diabetes Care.

[37]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[38]  A. Algra,et al.  Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials , 2010, The Lancet.

[39]  H. Gardarsdottir,et al.  The Association Between Patient-Reported Drug Taking and Gaps and Overlaps in Antidepressant Drug Dispensing , 2010, The Annals of pharmacotherapy.

[40]  J. Grinyó,et al.  Malignancy after renal transplantation: the role of immunosuppression , 2010, Nature Reviews Nephrology.

[41]  D. Tindall,et al.  Effect of dutasteride on the risk of prostate cancer. , 2010, The New England journal of medicine.

[42]  H. Gardarsdottir,et al.  Construction of drug treatment episodes from drug-dispensing histories is influenced by the gap length. , 2010, Journal of clinical epidemiology.

[43]  M. García-Closas,et al.  CEBP Focus: Biomarkers and Biospecimens , 2010 .

[44]  E. Banks,et al.  Recent declines in breast cancer incidence: mounting evidence that reduced use of menopausal hormones is largely responsible , 2010, Breast Cancer Research.

[45]  Jacques Ferlay,et al.  NORDCAN – a Nordic tool for cancer information, planning, quality control and research , 2010, Acta oncologica.

[46]  J. Manson,et al.  Breast cancer after use of estrogen plus progestin in postmenopausal women. , 2009, The New England journal of medicine.

[47]  S. Schneeweiss,et al.  Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data , 2007, Cancer Causes & Control.

[48]  J. Baron,et al.  Aspirin may be more effective in preventing colorectal adenomas in patients with higher BMI (United States) , 2006, Cancer Causes & Control.

[49]  J. Buring,et al.  Metabolic Abnormalities and Risk for Colorectal Cancer in the Physicians' Health Study , 2006, Cancer Epidemiology Biomarkers & Prevention.

[50]  J. Baron,et al.  A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. , 2006, Gastroenterology.

[51]  S. Solomon,et al.  Celecoxib for the prevention of sporadic colorectal adenomas. , 2006, The New England journal of medicine.

[52]  S. Solomon,et al.  Celecoxib for the prevention of colorectal adenomatous polyps. , 2006, The New England journal of medicine.

[53]  J. Manson,et al.  Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. , 2005, JAMA.

[54]  L. Kemény,et al.  Skin cancers after organ transplantation. , 2003, The New England journal of medicine.

[55]  G. Beck,et al.  A randomized trial of aspirin to prevent colorectal adenomas. , 2003, The New England journal of medicine.

[56]  Michael M Lieber,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[57]  S. Hasan,et al.  Comparability and Quality Control in Cancer Registration; Karachi (data monitoring 1995-2001). , 2002, JPMA. The Journal of the Pakistan Medical Association.

[58]  J. Robins,et al.  Marginal Structural Models and Causal Inference in Epidemiology , 2000, Epidemiology.

[59]  J. Manson,et al.  Aspirin Use and Colorectal Cancer: Post-Trial Follow-up Data from the Physicians' Health Study , 1998, Annals of Internal Medicine.

[60]  B. Rosner,et al.  An epidemiologic study of abuse of analgesic drugs. Effects of phenacetin and salicylate on mortality and cardiovascular morbidity (1968 to 1987) , 1991, The New England journal of medicine.

[61]  H. Tómasson,et al.  The copenhagen case‐control study of renal pelvis and ureter cancer: Role of analgesics , 1989, International journal of cancer.

[62]  K. Rothman Induction and latent periods. , 1981, American journal of epidemiology.

[63]  A. Upton,et al.  Future directions in cancer prevention. , 1980, Preventive medicine.

[64]  B. Henderson,et al.  Genital-tract cancers in adolescents and young adults. , 1972, The New England journal of medicine.

[65]  A. Herbst,et al.  Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. , 1971, The New England journal of medicine.

[66]  Julian P T Higgins,et al.  Biases in Randomized Trials: A Conversation Between Trialists and Epidemiologists. , 2017, Epidemiology.

[67]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[68]  J. Hallas,et al.  Long-Term Lithium Use and Risk of Renal and Upper Urinary Tract Cancers. , 2016, Journal of the American Society of Nephrology : JASN.

[69]  Andrew H. Beck,et al.  Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression , 2015, Modern Pathology.

[70]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[71]  F. Sitas IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (incl Sitas F.) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. A Review of Human Carcinogens , 2011 .

[72]  Organización Mundial de la Salud Guidelines for ATC classification and DDD assignment , 1996 .

[73]  A. Herbst,et al.  Clear cell adenocarcinoma of the vagina and cervix secondary to intrauterine exposure to diethylstilbestrol. , 1990, Seminars in surgical oncology.

[74]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[75]  T. Hutchinson,et al.  Analgesic use, blood dyscrasias, and case-control pharmacoepidemiology. A critique of the International Agranulocytosis and Aplastic Anemia Study. , 1987, Journal of chronic diseases.

[76]  A R Feinstein,et al.  The case-control study: valid selection of subjects. , 1985, Journal of chronic diseases.

[77]  M. Graffar [Modern epidemiology]. , 1971, Bruxelles medical.